Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of garetosmab in adults with fibrodysplasia ossificans progressiva
CTR20233450Phase 3Active
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in fibrodysplasia ossificans progressiva (FOP) comparing garetosmab with placebo (2 arms). Primary endpoints: Number of new heterotopic ossification lesions and Incidence and severity of adverse events of special interest. Started Jan 2024; status: active.
02
Drugs
garetosmab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on CTR20233450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233450.